Antiphospholipid syndrome presents with aortic thrombosis and central venous catheter-related thrombosis: a case report Authors: Yujiao Chen, Dongjing Li, Yinghong Su, Yulong Zhang Published: 2025 ABSTRACT AbstractBackgroundAntiphospholipid syndrome (APS) is a prothrombotic autoimmune disorder in which perioperative factors—particularly cardiopulmonary bypass—may amplify hypercoagulability. Evidence and consensus guidance for APS management around cardiovascular surgery remain limited.Case summaryA 37-year-old man with a large, highly mobile thrombus in the ascending aorta underwent surgical thrombectomy under cardiopulmonary bypass. Preoperative testing showed only leukocytosis, slightly shortened activated partial thromboplastin time (APTT) and mild D-dimer elevation; all other findings were unremarkable. Ten days postoperatively, removal of a nontunneled right internal jugular central venous catheter (CVC) was unexpectedly impeded by catheter-related thrombosis (CRT) despite prophylactic anticoagulation. Noninvasive maneuvers failed to free the catheter, necessitating open surgical extraction. Subsequent evaluation revealed widespread venous thromboses and confirmed APS, likely underlying both the arterial event and the rapidly developing catheter-associated thrombosis. Aggressive multimodal therapy—including methylprednisolone, enteric-coated aspirin, warfarin, rituximab, unfractionated heparin, and fibrinogenase—achieved clinical stabilization and prevented further events.ConclusionThis case highlights the challenges in timely diagnosing APS and the management complexity of rapid, postoperative thrombus formation. Clinicians should maintain a high index of suspicion for early postoperative hypercoagulability—even when routine coagulation screens are unrevealing—escalate promptly when CVC removal meets resistance, and consider APS-tailored antithrombotic strategies. The possibility that fibrin sheaths and catheter-associated thrombosis can evolve quickly, even after short indwelling times, warrants vigilance and early multidisciplinary intervention. It also raises concern that, in this context, standard direct oral anticoagulants (DOACs) may be less effective.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12959-025-00815-8.Keywords: Antiphospholipid syndrome, Thrombectomy, Catheter-related thrombosis, Aortic mural thrombus, Case report Introduction Aortic mural thrombus is uncommon and particularly rare in the ascending aorta and aortic arch, where mobile lesions carry a high risk of systemic embolization. Although individual series and meta-analyses suggest that proximal, highly mobile thrombi may warrant early operative therapy, formal consensus guidance remains limited, and management is often individualized [1]. CVCs are indispensable in cardiothoracic care; however, difficult or failed removal—typically due to fibrin sheath formation or catheter–wall adhesion—is considered uncommon and is classically associated with long indwelling times rather than short-term perioperative use. When removal is impeded, the risks include vascular injury, retained fragments, and thromboembolism [2]. Against this background, we report a distinctive case of a young man with a large, highly mobile thrombus in the ascending aorta requiring surgical thrombectomy, followed—within days—by acute, catheter-associated thrombosis that rendered a right internal jugular CVC “stuck” despite anticoagulant prophylaxis. The subsequent diagnosis of APS provides a unifying explanation for both the arterial presentation and the rapidly evolving catheter-related thrombosis (CRT). To our knowledge, reports of early postoperative CVC entrapment from acute thrombosis in the context of APS and recent cardiopulmonary bypass are scarce. This case underscores three practical messages: (i) vigilance for postoperative hypercoagulability even when routine coagulation screens are unrevealing; (ii) early multidisciplinary escalation when CVC removal meets unexpected resistance; and (iii) the importance of APS-tailored antithrombotic strategies, given accumulating evidence that standard direct oral anticoagulants may be suboptimal in this setting. Case report A 37-year-old man (60 kg, 173 cm; American Society of Anesthesiologists [ASA] physical status II) presented with a 2-month history of bilateral lower-limb soreness and weakness and was admitted to the orthopedic department with a provisional diagnosis of lumbar degenerative disease. The patient had a significant smoking history (30 cigarettes per day). Computed tomography angiography (CTA) performed after admission revealed multiple calcified plaques along the arterial walls, with a suspected thrombus in the ascending aorta (Fig. 1A) and luminal narrowing of the lower-extremity arteries (Fig. 1B). Duplex ultrasonography demonstrated a flocculent mass (~ 42 mm × 8.3 mm) oscillating at the origin of the aortic arch without disturbance of blood flow (Fig. 1C, D), and reduced flow velocities in the anterior and posterior tibial arteries, peroneal artery, and dorsalis pedis artery (Fig. 1E). Laboratory tests showed marked leukocytosis (white blood cell count 24.96 × 10⁹/L; neutrophils 22.97 × 10⁹/L), which subsequently normalized following treatment with cefoperazone-sulbactam. Other parameters remained within normal limits. The patient was promptly transferred to the department of cardiovascular surgery and underwent resection of the ascending aortic mass under cardiopulmonary bypass. A right internal jugular 8-Fr triple-lumen CVC was inserted to a depth of 12 cm. The intraoperative course and the immediate postoperative period were uneventful. Histopathological examination later confirmed that the aortic mass was a thrombus containing necrotic debris and inflammatory exudate (Fig. 1F). Multi-Modal Imaging and Pathological Correlation of Aortic Neoplasms and Systemic Atherosclerosis. (A) Upper body CTA examination reveals calcified plaques at the aortic arch, thoracic aorta, abdominal aorta, origin of the celiac trunk, and left coronary artery wall. A nodular hypodense shadow is seen within the lumen of the aortic terminal, suggesting possible localized dissection (calcified plaques indicated by yellow arrows). (B) Lower extremity CTA demonstrates: (1) diffuse atherosclerotic plaques in the distal abdominal aorta, bilateral common iliac arteries, left internal iliac artery, and left external iliac artery, with mild luminal stenosis; (2) a mixed plaque in the right external iliac artery to proximal femoral artery, causing severe luminal stenosis. The right superficial femoral artery appears slightly narrower compared to the contralateral side (calcified plaques indicated by yellow arrows). (C) In systole, an neoplasm (red arrow) within the aortic arch measures approximately 42 mm in length, with a maximal width of about 8.3 mm. (D) The same neoplasm (red arrow) observed during left ventricular diastole. (E) Doppler ultrasound shows slowed blood flow in the left anterior tibial artery with a tardusparvus waveform. (F) Microscopic examination reveals the neoplasm on the aortic intima composed of thrombus, necrotic material, and inflammatory exudate During the indwelling period, routine catheter care was maintained. The catheter remained intact, without leakage, obstruction, or a “mechanical valve” phenomenon. The patient received rivaroxaban (15 mg twice daily), enteric-coated aspirin (0.1 g once daily), sarpogrelate hydrochloride (100 mg three times daily), and atorvastatin calcium (20 mg nightly). Serial coagulation tests showed progressive increases in D-dimer, fibrinogen, and fibrin degradation products, whereas the remaining coagulation indices were stable (Table 1). On postoperative day 10, after normalization of clinical parameters, CVC removal was attempted. Resistance was encountered after approximately 4 cm of withdrawal, and the catheter could not be completely removed. Bedside ultrasound demonstrated limited proximal catheter mobility without evidence of thrombosis or kinking, raising concern for adhesion to a cardiac valve (Fig. 2A). Emergency chest CT was unremarkable (Fig. 2B, C). The differential diagnosis included catheter adhesion to a valve, fibrin sheath formation, and occult thrombus. Table 1Coagulation parametersPostoperative DayPT(s)INRPT%(%)APTT(s)TT(s)FIB(g/L)P-FDP(Ug/ml)ATIII(%)D-D(Ug/ml)-211.800.95110.0022.50 ↓16.703.612.90122.401.19 ↑013.601.1280.9028.3019.502.982.7091.500.90214.001.1674.5033.2014.308.80 ↑4.80109.501.43 ↑315.90 ↑1.34 ↑60.40 ↓43.80 ↑14.1010.98 ↑5.60 ↑89.401.66 ↑414.60 ↑1.22 ↑70.5065.00 ↑75.60 ↑11.20 ↑10.10 ↑94.603.51 ↑516.70 ↑1.42 ↑55.60 ↓35.6012.90 ↓10.82 ↑18.80 ↑116.306.74 ↑613.601.1280.9036.8013.60 ↓10.65 ↑19.90 ↑116.907.69 ↑812.500.98109.0026.0015.805.30 ↑18.60 ↑100.503.91 ↑1013.201.1689.0030.2018.606.60 ↑17.60 ↑97.005.82 ↑Normal range: PT 10–14; INR 0.8–1.2; PT% 70–130; APTT 24–39; TT 14–21; FIB 2–4; P-FDP 0–5; ATIII 80–130; D-D 0–1PT: Prothrombin Time; INR: International Normalized Ratio; PT%: Prothrombin Time Activity; APTT: Activated Partial Thromboplastin Time; TT: Thrombin Time; FIB: Fibrinogen; P-FDP: Plasma Fibrin Degradation Products; ATIII: Antithrombin III; D-D: D-Dimer Coagulation parameters Normal range: PT 10–14; INR 0.8–1.2; PT% 70–130; APTT 24–39; TT 14–21; FIB 2–4; P-FDP 0–5; ATIII 80–130; D-D 0–1 PT: Prothrombin Time; INR: International Normalized Ratio; PT%: Prothrombin Time Activity; APTT: Activated Partial Thromboplastin Time; TT: Thrombin Time; FIB: Fibrinogen; P-FDP: Plasma Fibrin Degradation Products; ATIII: Antithrombin III; D-D: D-Dimer Imaging at 3 days post‑ascending aortic neoplasm resection shows no thrombosis around the central venous catheter. (A) Bedside ultrasound demonstrates no thrombus adjacent to the central venous catheter; red arrow indicates catheter position. (B) Chest radiograph reveals no abnormalities; red arrow denotes the catheter. (C) CT scan similarly shows no thrombus around the catheter; red arrow marks the catheter location Five days later, after ongoing anticoagulation, a second removal attempt was scheduled. Pre-removal ultrasonography revealed a thrombus (~ 0.82 cm × 0.45 cm) attached to the catheter tip (Fig. 3A). The patient was transferred to an interventional suite, where several nonsurgical techniques were attempted, including the Hong method (guidewire-and-sheath technique) [3], guidewire-reinforced traction [4], and retrograde femoral venous access (Videos 1 and 2); all attempts failed. Angiography did not demonstrate a definite intravascular thrombus (images not recorded), and interventional retrieval was abandoned. The patient subsequently underwent open surgical exploration and CVC removal, which revealed that the catheter was extensively encased in thrombus (Fig. 3B). Pathological examination confirmed a mixed thrombus (Fig. 3C). Catheter-related thrombus after 5 days of anticoagulation therapy. (A) Ultrasound reveals a thrombus at the tip of the central venous catheter (green shaded area), measuring approximately 0.82 cm × 0.45 cm; red arrow indicates catheter tip. (B) Intraoperative view during catheter removal; the green circle highlights the thrombus retrieved via the right internal jugular vein. (C) Histopathological analysis identifies the thrombus as a mixed thrombus Following catheter removal, the previous treatment regimen was continued. Three days later, new thrombi were detected in multiple veins, including the right internal jugular, brachiocephalic, subclavian, external jugular, and cubital veins, as well as the left subclavian and cephalic veins (Fig. 4A–D). Antiphospholipid syndrome (APS) was suspected, and antiphospholipid antibody testing was performed. The results were as follows: anticardiolipin (aCL) IgG 63.4 GPL, aCL IgM 54.8 MPL, anti-β₂-glycoprotein I (aβ₂GPI) IgG 86.9 GPL, aβ₂GPI IgM 45.4 MPL. The reference ranges were: negative < 15 GPL/MPL, weakly positive 15–39.9 GPL/MPL, positive 40–79.9 GPL/MPL, and strongly positive ≥ 80 GPL/MPL. The patient was then treated with methylprednisolone (intravenous, 1 g once daily for 3 consecutive days), enteric-coated aspirin (oral, 100 mg once daily), iloprost (as an adjunct for distal ischemia, 0.5 ng/kg/min by intravenous infusion for 6 h per day for 5 consecutive days), and warfarin (once daily, initial dose 3 mg, with subsequent adjustment to maintain an international normalized ratio [INR] of 2.0–3.0). Rituximab was administered at 375 mg/m² body surface area once weekly by intravenous infusion at 50 mg/h for a total of four doses. Unfractionated heparin, which was initiated with a bolus of 80 U/kg followed by continuous infusion at 18 U/kg/h (adjusted according to APTT to 1.5–2.5 times the normal value), was discontinued after the INR reached 3.0 (6 days in this patient). Hydroxychloroquine was prescribed orally at 2.5 mg/kg twice daily and was intended for long-term use; however, it was discontinued on day 5 because of an allergic reaction characterized by urticaria and pruritus. Fibrinogenase was administered by intravenous infusion to alleviate lower-limb ischemic symptoms (100 units on day 1, followed by 200 units once daily for 7 days). Multifocal venous thrombosis detected 3 days post-catheter removal. (A) Extensive thrombus present in the left subclavian vein. (B) Extensive thrombus observed in the right brachiocephalic vein. (C-D) Thrombus in the brachial segment (C) and proximal forearm segment (D) of the left cephalic vein. (thrombus indicated by red arrows) After 10 days of this comprehensive therapy, thrombus progression was arrested, and therapeutic anticoagulation was achieved. The patient was discharged on warfarin and enteric-coated aspirin and was advised to quit smoking. After discharge, he was followed up twice weekly, and medications were adjusted according to laboratory findings. No new thrombotic or bleeding events occurred. Twelve weeks after the previous antiphospholipid antibodies assessment, a second antiphospholipid antibodies panel showed the following titers: aCL IgG 48.8 GPL, aCL IgM 31.5 MPL, aβ₂GPI IgG 62.1 GPL, aβ₂GPI IgM 25.7 MPL. These findings confirmed the diagnosis of APS. Discussion This case describes an unusually rapid sequence of arterial and catheter-related thromboses in a postoperative cardiac surgery patient, ultimately diagnosed with APS. It illustrates how APS may accelerate thrombus formation in both arterial and venous systems over a short interval, and how diagnosis can be delayed when routine coagulation tests are unrevealing and APS-specific testing is deferred. Primary aortic mural thrombi in ascending aorta or arch are exceptionally rare; most reported mural thrombi arise in the descending thoracic or abdominal aorta. They may remain silent until embolization results in stroke, visceral ischemia, or acute limb ischemia [5–7]. In the absence of randomized trials or formal guidelines, many authors advocate aggressive treatment of mobile ascending or arch thrombi because of their presumed high embolic risk and the limitations of anticoagulation alone [8]. In this context, urgent surgical thrombectomy under cardiopulmonary bypass was a reasonable choice and is consistent with published case-based practice. Aortic mural thrombosis typically arises from interacting factors: underlying arterial wall pathology, systemic hypercoagulability, local flow abnormalities, and less common entities such as eosinophilic aortitis. In this patient, widespread vascular calcifications suggested pre-existing structural disease. Routine coagulation tests obtained immediately preoperatively were at most mildly abnormal and later normalized, offering little clue to an occult thrombophilia. Because antiphospholipid antibody testing is costly, the patient initially declined testing after discussion of risks, benefits, and financial considerations, delaying recognition of the underlying prothrombotic state. The subsequent development of a central venous CRT around postoperative day 10 was striking, as such thrombi seldom become adherent within a few weeks [9]. Rising D-dimer, plasma fibrin degradation products (P-FDP), and fibrinogen levels were the earliest signals of an evolving process, although individually nonspecific. Serial duplex ultrasonography, CT angiography, and venography were initially negative, likely reflecting small thrombus volume, low radiographic density, and close molding along the catheter and venous wall. This experience emphasizes that normal vascular imaging does not reliably exclude CRT when clinical suspicion is high; repeat evaluation and attention to laboratory trends may be necessary. When bedside removal failed, the team opted for surgical venotomy. This cautious, multidisciplinary strategy aligns with recommendations to avoid forcible extraction, which can cause catheter fracture, venous avulsion, embolization, or even tamponade [9]. Intraoperative findings confirmed extensive thrombus encircling the catheter, affirming that aggressive bedside attempts could have precipitated embolic complications. Some guidelines (e.g. Korean Society of Hematology, 2021) endorse 3–5 days of anticoagulation before removal—but our case suggests that extended or intensified therapy may be warranted when thrombus persists [10]. Given the combination of widespread arterial thromboses and CRT, alternative causes were systematically evaluated. There was no clinical or laboratory evidence of malignancy, heparin-induced thrombocytopenia, disseminated intravascular coagulation, thrombotic microangiopathy, or systemic vasculitis. Infection was present but its severity and time course did not fully explain the breadth and tempo of thrombosis, and it was considered more likely a trigger than a primary cause. APS, defined by persistent antiphospholipid antibody positivity in association with thrombotic and/or obstetric events, provides a unifying explanation for the arterial and venous events observed. In the acute setting, however, formal classification criteria cannot be met because they require repeat testing at least 12 weeks apart. In this patient, positivity for anticardiolipin and anti-β₂ glycoprotein I antibodies, while lupus anticoagulant was not assessed because testing is unreliable during anticoagulation, was consistent with APS. The rapid, multisite thrombosis raised concern for an evolving catastrophic APS-like picture, even though full criteria may not have been satisfied. The delay in recognizing APS contributed to postponement of disease-directed treatment and illustrates the limitations of relying on standard coagulation assays. In patients with unexplained, rapidly progressive, or multisite thrombosis—especially involving both arterial and venous systems—early consideration of APS and timely antibody testing are warranted, despite normal routine coagulation parameters. The patient initially received rivaroxaban, aspirin, sarpogrelate, and atorvastatin. This regimen primarily targeted peripheral arterial disease and CRT rather than APS specifically. Clinical trials have shown that low-dose rivaroxaban in combination with aspirin can reduce major cardiovascular and limb events in patients with chronic coronary artery disease and/or peripheral arterial disease [11]. However, current guidelines generally favor unfractionated or low molecular weight heparin, followed by vitamin K antagonists, for thrombotic APS, and restrict rivaroxaban to carefully selected low-risk venous cases [12]. Evidence for sarpogrelate in APS is lacking, and statins appear mainly to improve laboratory markers rather than proven clinical outcomes [13]. After APS-directed therapy was instituted, the patient remained clinically stable without further thrombotic events during subsequent follow-up. Although a single case cannot determine comparative efficacy of specific regimens, it underscores key principles: maintain a high index of suspicion for APS in patients with unexplained, rapidly progressive, or multisite thrombosis affecting both arterial and venous systems; do not rely solely on normal routine coagulation tests to exclude APS; align anticoagulant choices with APS-focused evidence; and manage suspected CRT conservatively, avoiding forcible catheter removal and using multidisciplinary planning to reduce embolic and procedural risks. Limitations This report has several important limitations. First, as a single-patient case report, it provides only descriptive information and cannot establish causality or be readily generalized to other patients with APS-related thrombosis. Second, a retrospective description of a single patient also precludes controlled comparisons with alternative diagnostic or anticoagulation strategies. Third, the choice and sequencing of antithrombotic and immunomodulatory therapies were driven by evolving clinical status and multidisciplinary judgment rather than a predefined protocol. Finally, although short-term stabilization without recurrent thrombosis was observed, long-term outcomes, including durability of anticoagulation, risk of relapse, and late complications, remain unknown. These limitations indicate that the observations in this report should be interpreted with caution and ideally confirmed or refined in larger, prospective cohorts or controlled studies. Conclusion This case underscores the potential for APS to cause rapidly progressive, multisite thrombosis involving both large arteries and CVCs in the postoperative setting. The sequence of an ascending aortic mural thrombus followed by extensive CRT highlights the need to consider APS in patients with unexplained, recurrent, or combined arterial and venous events. Our experience emphasizes early use of APS-specific antibody testing, avoidance of forceful catheter manipulation, and timely transition from direct oral anticoagulants to warfarin-based, high-intensity anticoagulation with adjunctive immunosuppression. Prompt recognition and comprehensive management were crucial to stabilizing disease and preventing further complications. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements None. Abbreviations Antiphospholipid syndrome Central venous catheter Anticardiolipin Activated partial thromboplastin time American Society of Anesthesiologists Anti-β₂-glycoprotein I Catheter-related thrombosis Computed tomography Computed tomography Angiography D-dimer Direct oral anticoagulants Figure French IgG phospholipid units Immunoglobulin G Immunoglobulin M International normalized ratio Low molecular weight heparin IgM phospholipid units Fibrin degradation products Author contributions Conception and design: YC, YZ. Analysis and interpretation of the data: YC, DL. Drafting of the article: YC, DL, YS. Collection and compilation of the case and pictures: DL, YS. Critical revision of the article for important intellectual content: YC, YS, YZ. All authors read and approved the final version of the manuscript. Funding This study was supported by the Research Development Program of North Sichuan Medical College (No. CBY21-QA63). Data availability The datasets used and analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate Not applicable. Consent for publication The written informed consent for publication was obtained from the patient. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement The datasets used and analysed during the current study are available from the corresponding author on reasonable request.